Company’s PowerLook® Tomo Detection Solution Recognized as “Best New Radiology Solution”
NASHUA, N.H., June 06, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD ), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its PowerLook® Tomo Detection solution has been selected as the winner of the “Best New Radiology Solution” award by MedTech Breakthrough , an independent organization recognizing the top companies, technologies and products in the global health and medical technology market.
“We are proud to be recognized by MedTech Breakthrough as a leading medical technology company providing innovative solutions that support radiologists in how they manage and interpret digital breast tomosynthesis (DBT) data,” stated Ken Ferry, president and CEO at iCAD. “It is exciting to see the impact that PowerLook Tomo Detection has had on revolutionizing breast cancer detection acknowledged by those in our industry.”
The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including robotics, clinical administration, telehealth, patient engagement, electronic health records (EHR), mHealth, medical devices, medical data, and more. This year’s program attracted over 3,000 nominations from more than 12 different countries across the world.
“iCAD is delivering leading-edge technology with PowerLook Tomo Detection, an innovative radiologist workflow solution that incorporates artificial intelligence (AI) to support and optimize workflow efficiencies and decision making,” said James Johnson, managing director, MedTech Breakthrough. “The use of AI and deep learning in healthcare is one of the most exciting and promising developments in the medical technology industry. We congratulate iCAD on their well-deserved industry recognition and look forward to seeing continued success with their innovative solutions.”
PowerLook Tomo Detection is the first and only FDA-approved concurrent-read cancer detection solution for DBT. The technology utilizes a trained algorithm developed through deep learning that automatically analyzes each tomosynthesis plane. Suspicious areas identified are then blended into a 2D synthetic image to provide radiologists with a single, highly sensitive, enhanced image that is used to easily navigate the tomosynthesis datasets.
About iCAD, Inc. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2017, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contact:
Media Inquiries:
ARPR Erin Bocherer, (855) 300-8209 erin@arpr.com
or
Investor Relations: LifeSci Advisors Jeremy Feffer, (917) 749-1494 jeremy@lifesciadvisors.com
About MedTech Breakthrough The MedTech Breakthrough Awards program, part of the Tech Breakthrough Awards organization, is devoted to honoring excellence in medical and health related technology companies, products and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough MedTech companies and products in categories including Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Genomics, Medical Data, Healthcare Cybersecurity and more. For more information visit www.MedTechBreakthrough.com .
